Can-Fite granted patent on the manufacturing of CF101 in Japan
This patent describes a method for the chemical synthesis of the A3 adenosine receptor agonist, IB-MECA, which is the active pharmaceuticals ingredient (API) of the CF101 drug candidate.
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Metabolon has signed several research collaboration and licensing agreements with Patia Biopharma related to use of Metabolon’s Quantose IR technology, a blood test for prediabetes that reflects insulin